Century Therapeutics presents CNTY-813 data: what it means for Century Therapeutics stock

Published on 10/16/2026 at 02:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Century Therapeutics stock has a Q4 2026 IND milestone and a November 18 conference date. CNTY-813 held glycemic control for over 11 months in mice at EASD.

Clinical milestones and financial context

CNTY-813 maintained glycemic control for more than 11 months in a diabetic mouse study on October 2, 2026.
Century Therapeutics reported adjusted? no, GAAP diluted earnings per share of minus USD 0.17 for the second quarter of 2026 against minus USD 0.11 consensus.
Century Therapeutics will attend the Jefferies Global Healthcare Conference on November 18, 2026.

IPSC, US15673T1007, Illustration mit AI erstellt.

Century Therapeutics (ISIN US15673T1007) said on October 2, 2026, that its CNTY-813 therapy maintained glycemic control for more than 11 months in a diabetic mouse study, according to Century Therapeutics. On October 14, 2026, the company announced that it will attend the Jefferies Global Healthcare Conference on November 18, 2026.

What does the filing milestone mean?

The central development milestone is an Investigational New Drug application for CNTY-813 in the fourth quarter of 2026. Century said initial clinical data from a first-in-human study are anticipated in the second half of 2027, subject to completion of the remaining studies. The program uses iPSC-derived islets engineered with Allo-Evasion 5.0 for type 1 diabetes.

The October 2 release also described five clinical-scale manufacturing batches, a 29-day process that exceeded purity criteria at every stage, and successful engraftment in rat livers after portal-vein delivery. The study findings remain nonclinical, so the next value test is the transition from animal data to regulatory and clinical execution.

Three milestones since August

On August 12, 2026, Century reported second-quarter diluted earnings per share of minus USD 0.17 against a consensus estimate of minus USD 0.11, a miss of USD 0.06, according to MarketBeat. On October 2, the company presented the CNTY-813 data at the European Association for the Study of Diabetes meeting. On October 14, it scheduled its November 18 investor conference appearance.

Dates that could move the story

Century Therapeutics is scheduled to report its next earnings on November 5, 2026, according to Investing.com. The Jefferies Global Healthcare Conference follows on November 18, 2026, while the company targets the fourth quarter of 2026 for the CNTY-813 filing.

Cash and development risk

Century reported USD 49.64 million in cash and cash equivalents at June 30, 2026, while operating cash flow was negative USD 19.83 million in the second quarter. Diluted earnings per share were minus USD 0.17 for that quarter. The figures underline why the regulatory timetable and financing discipline matter alongside the preclinical results.

Market context for investors

Century Therapeutics has a market capitalization of USD 271.6 million and a 52-week range of USD 0.43 to USD 3.04, based on the latest market snapshot dated October 15, 2026. The company is listed on the Nasdaq Capital Market under the ticker IPSC and operates in biotechnology and medical research.